What does the evidence say about Maca Menopause Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Maca Menopause Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Background: Middle-aged women frequently experience diverse physical and psychological symptoms, including depression, anxiety, sleep disturbances, vasomotor symptoms, and reduced quality of life, during menopause. [Kim JH (2025); evidence level 1] - Risk of bias was assessed using the Cochrane risk of bias tool, and meta-analyses were performed using a random effects model. [Kim JH (2025); evidence level 1] - Results: Nonpharmacological interventions significantly reduced symptoms of depression (standardized mean difference (SMD) = -1.10), anxiety (-0.82), sleep disturbances (-0.90), menopausal symptoms (-1.18), and hot flashes (-0.34). [Kim JH (2025); evidence level 1] - With increasing concerns regarding the side effects of hormone therapy, nonpharmacological interventions have emerged as safer alternatives for symptom management. [Kim JH (2025); evidence level 1] - Data synthesis was performed with RevMan 5.4, and the certainty of the evidence was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. [de Aquino ACQ (2025); evidence level 1] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.